Pfizer (PFE) and Valneva (VALN) EMA validates Lyme vaccine MAA
EMA validates the marketing authorization application for PF-07307405, based on the Phase 3 VALOR trial in more than 9,400 participants aged five years and older, reporting more than 70% efficacy and no safety concerns.